We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Dr Mar Tintoré and Dr Álvaro Cobo Calvo
Anti-Müllerian hormone had been proposed as a potential biomarker for predicting disease prognosis in women, but this study shows that the observed association is explained by patients’ chronological age.
A study led by the Clinical Neuroimmunology Group at the Vall d’Hebron Research Institute (VHIR) and the Multiple Sclerosis Centre of Catalonia (Cemcat) has concluded that ovarian ageing, measured at disease onset through anti-Müllerian hormone (AMH) levels, has no predictive value for the course of multiple sclerosis or for long-term disability. The study, published in the Journal of Neurology, Neurosurgery and Psychiatry, involved collaboration with the VHIR groups in Clinical Biochemistry, Drug Delivery and Therapy, Neuroradiology, and Maternal and Fetal Medicine, as well as with the Gregorio Marañón University Hospital and Ramón y Cajal University Hospital.
Anti-Müllerian hormone is a protein produced by the ovaries that is commonly used as an indicator of ovarian reserve, that is, the number of remaining oocytes in women. This reserve naturally declines with age and is one of several factors that may be associated with biological ageing in women. Previous studies had proposed AMH as a potential biomarker associated with disease activity and prognosis in women with multiple sclerosis.
To investigate this relationship, the research team analysed prospective data from three hospitals: Vall d’Hebron University Hospital in Barcelona and the Gregorio Marañón and Ramón y Cajal University Hospitals in Madrid.
The study included 365 women aged between 20 and 45 years who had experienced a first episode suggestive of multiple sclerosis and whose AMH levels had been measured shortly after their first demyelinating event. The patients were followed for several years to assess different indicators of disease progression, including the occurrence of a second relapse, disability progression, and the diagnosis of multiple sclerosis according to the McDonald criteria.
The results show that anti-Müllerian hormone levels are not associated with either a better or a worse prognosis in multiple sclerosis. “When we adjust for patient age, we demonstrate that this hormone has no predictive value. The possible association observed in previous studies between AMH and prognosis appears to be largely explained by patients’ age, with which this hormone is closely correlated”, explains Dr. Álvaro Cobo Calvo, neurologist in the Department of Neurology at Vall d’Hebron University Hospital and Cemcat, and researcher in the Clinical Neuroimmunology group at VHIR.
Chronological age—that is, a patient’s actual age in years—is one of the most relevant factors in the prognosis of multiple sclerosis: older individuals at disease onset tend to develop greater disability. Although older women generally have lower AMH levels, the levels of this hormone do not exert an independent effect on disease progression.
The researchers also compared AMH levels in patients with multiple sclerosis with those of 145 healthy women and found no differences between the two groups.
These findings have important implications for clinical practice, particularly in providing evidence-based information to women with diminished ovarian reserve or premature ovarian insufficiency. “These results help clarify a question that had generated considerable interest in previous studies but had not been confirmed in cohorts of this size or with such rigorous statistical adjustment. We have confirmed that low ovarian reserve is not an additional risk factor for long-term disability”, concludes Dr. Mar Tintoré, Clinical Head of the Department of Neurology/Neuroimmunology at Vall d’Hebron University Hospital and Cemcat, and principal investigator of the Clinical Neuroimmunology group at VHIR.
Clinical neuroimmunology, General Hospital
Neurology, General Hospital
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.